Allergy and Immunology · Birmingham, AL
NPI
1568807378
Since 2013
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
504 Brookwood Blvd
Birmingham, AL, 35209
Phone (205) 871-9661
Groups this clinician bills Medicare through
Medicare paid, 2024
$457K
23,860 services
Medicare patients, 2024
182
Average age 72
Drug cost, 2024
$2.7M
1,784 prescriptions
Company payments, 2025
$5,285
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Polcari was code J2357 (injection, omalizumab, 5 mg), 6,810 times for 30 patients. In total Michael Polcari billed 23,860 services in 38 codes, and Medicare paid $457K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2357 Injection, omalizumab, 5 mg | Office | 6,810 | 30 | $29.76 | $203K |
| 95004 Test - Miscellaneous | Office | 690 | 14 | $2.35 | $1,622 |
| 95117 Treatment - Miscellaneous | Office | 328 | 40 | $7.76 | $2,544 |
| 95165 Treatment - Miscellaneous | Office | 251 | 11 | $9.04 | $2,270 |
| 96401 Chemotherapy Administration | Office | 237 | 42 | $48.85 | $12K |
| 95024 Test - Miscellaneous | Office | 95 | 11 | $5.40 | $513 |
| 99214 Office E&M - Established | Office | 84 | 59 | $81.45 | $6,842 |
| 96160 E&M - Miscellaneous | Office | 51 | 38 | $1.84 | $93.6 |
| 96372 Injection Administration | Office | 33 | 16 | $4.84 | $160 |
| 99204 Office E&M - New | Office | 29 | 29 | $114.11 | $3,309 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 25 | 25 | $12.09 | $302 |
| 99215 Office E&M - Established | Office | 22 | 20 | $129.17 | $2,842 |
| 99205 Office E&M - New | Office | 15 | 15 | $137.94 | $2,069 |
| 99213 Office E&M - Established | Office | 15 | 14 | $56.63 | $849 |
By year: 2022 $75K for 2,650 services; 2023 $362K for 17,120 services; 2024 $457K for 23,860 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael Polcari prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 183 prescriptions and refills. In total Michael Polcari wrote 1,784 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 183 | 269 | 44 | $169K |
| Azelastine Hcl Generic | 176 | 293 | 81 | $6,281 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 116 | 151 | 43 | $3,650 |
| Dupixent Pen Dupilumab | 116 | 116 | 15 | $424K |
| Ipratropium Bromide Generic | 88 | 131 | 35 | $4,425 |
| Montelukast Sodium Generic | 85 | 187 | 36 | $904 |
| Fluticasone Propionate Generic | 66 | 131 | 31 | $1,227 |
| Xolair Omalizumab | 59 | 61 | Under 11 | $209K |
| Prednisone Generic | 58 | 58 | 38 | $161 |
| Azithromycin Generic | 54 | 64 | 35 | $1,052 |
| Tacrolimus Generic | 51 | 65 | 13 | $12K |
| Epinephrine Generic | 49 | 51 | 43 | $11K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 48 | 60 | 19 | $36K |
| Dulera Mometasone/Formoterol | 45 | 69 | 11 | $23K |
| Dupixent Syringe Dupilumab | 41 | 41 | Under 11 | $152K |
Brand drugs: 856 claims; generic drugs: 913 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Polcari $5,285 ($5,285 in general payments such as food, travel and fees) from 28 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $889.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 27 | $889 |
| Regeneron Healthcare Solutions, Inc. REGN | 21 | $611 |
| CSL Behring CSL.AX | 14 | $391 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $359 |
| Genzyme Corporation SNY | 13 | $338 |
| GlaxoSmithKline, LLC. GSK | 21 | $334 |
| Genentech USA, Inc. ROG.SW | 13 | $316 |
| Amgen Inc. AMGN | 18 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 9 | $274 |
| LEO Pharma Inc. | 11 | $260 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.